natgillin/translations-raw huggingface dataset:
In the case of an amyloid negative initial visual read and an amyloid positive quantitation,
a. V primeru začetnega pozitivnega amiloidnega vizualnega odčitka in negativne kvantifikacije razmislite, ali bi lahko pozitivna vizualna interpretacija temeljila na
In all 59 subjects, a blinded PET reading by 5 nuclear medicine physicians resulted in a majority read sensitivity of 92% (95% CI: 78-98%) and specificity of 100% (95% CI: 80-100%).
Pri vseh 59 preiskovancih je pet specialistov nuklearne medicine opravilo slepo odčitavanje PET-slik, pri čemer je bila občutljivost večine odčitavanj 92 % (95-odstotni IZ:
A PET scan with florbetapir (18F) should be requested by physicians skilled in the clinical management of neurodegenerative disorders.
4.2 Odmerjanje in način uporabe PET-preiskavo s florbetapirjem (18F) mora naročiti zdravnik, usposobljen za klinično obravnavo nevrodegenerativnih bolezni.
4.4 Special warnings and precautions for use
4.4 Posebna opozorila in previdnostni ukrepi Utemeljitev koristi in tveganj za posameznika
What Amyvid looks like and contents of the pack Amyvid is a clear, colourless solution for injection.
Zdravilo Amyvid je bistra, brezbarvna raztopina za injiciranje.
Amyvid 800 MBq/mL solution for injection 7.5 hours from the ToC
Amyvid 800 MBq/ml raztopina za injiciranje 7,5 ur od ToC
(95% CI: 24.1-51.9%)
(95-odstotni IZ: 24,1-51,9 %)
Injection site reactiona Infusion site rash aInjection site reaction includes injection site haemorrhage, injection site irritation, and injection site pain
Splošne težave in spremembe na mestu aplikacije reakcija na mestu injiciranjaa izpuščaj na mestu infundiranja aReakcija na mestu injiciranja vključuje krvavitev na mestu injiciranja, iritacijo na mestu injiciranja in bolečino na mestu injiciranja.
Mechanism of action Florbetapir (18F) binds to β-amyloid neuritic plaques.
Florbetapir (18F) se veže na ß-amiloidne nevritične lehe.
(95% CI: 59.9-78.1%)
(95-odstotni IZ: 59,9-78,1 %)
Resuming breast-feeding should be in agreement with the nuclear medicine doctor who will supervise the procedure.
Za ponovno nadaljevanje dojenja se morate dogovoriti z zdravnikom nuklearne medicine, ki bo nadzoroval postopek.
Read the package leaflet before use.
POSTOPEK UPORABE Pred uporabo preberite priloženo navodilo.
Advanced Accelerator Applications, 62660, Beuvry, France Advanced Accelerator Applications, 01630, Saint Genis Pouilly, France Advanced Accelerator Applications, 53121, Bonn, Germany Advanced Accelerator Applications, 10010, Colleretto Giacosa, Italy Advanced Accelerator Applications, 86077, Pozzilli, Italy Advanced Accelerator Applications, 47014, Meldola, Italy Advanced Accelerator Applications, 50100, Zaragoza, Spain Catalana de Dispensación SAU, 08950, Barcelona, Spain
Advanced Accelerator Applications, 62660, Beuvry, Francija Advanced Accelerator Applications, 01630, Saint Genis Pouilly, Francija Advanced Accelerator Applications, 53121, Bonn, Nemčija Advanced Accelerator Applications, 10010, Colleretto Giacosa, Italija Advanced Accelerator Applications, 86077, Pozzilli, Italija Advanced Accelerator Applications, 47014, Meldola, Italija Advanced Accelerator Applications, 50100, Zaragoza, Španija Catalana de Dispensación SAU, 08950, Barcelona, Španija
Pruritus Urticaria
Trebušna slinavka
METHOD AND ROUTE(S) OF ADMINISTRATION Read the package leaflet before use Intravenous use
POSTOPEK IN POT(I) UPORABE ZDRAVILA Pred uporabo preberite priloženo navodilo!
1 vial
Ena viala
Diagnostic performance values of florbetapir (18F) PET are tabulated below:
Vrednosti diagnostične učinkovitosti PET-preiskave s florbetapirjem (18F) so navedene v spodnji tabeli:
Renal/hepatic impairment The pharmacokinetics in patients with renal or hepatic impairment have not been characterised.
Farmakokinetika pri bolnikih z ledvično ali jetrno okvaro ni bila določena.
Amyvid 1900 MBq/mL solution for injection 10 hours from the ToC.
Amyvid 1900 MBq/ml raztopina za injiciranje 10 ur od ToC
MARKETING AUTHORISATION NUMBER(S) EU/1/12/805/001 (10 mL)
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/12/805/001 (10 mL)
Advanced Accelerator Applications, 53121, Bonn, Germany Advanced Accelerator Applications, 10010, Colleretto Giacosa, Italy Advanced Accelerator Applications, 86077, Pozzilli, Italy Advanced Accelerator Applications, 47014, Meldola, Italy Advanced Accelerator Applications, 50100, Zaragoza, Spain Catalana de Dispensación SAU, 08950, Barcelona, Spain PETNET Solutions (Siemens Healthcare Limited), Nottingham, NG5 1PB, United Kingdom PETNET Solutions (Siemens Healthcare Limited), Northwood, HA6 2RN, United Kingdom PETNET Solutions, 91090, Lisses, France
Advanced Accelerator Applications, 10010, Colleretto Giacosa, Italija Advanced Accelerator Applications, 86077, Pozzilli, Italija Advanced Accelerator Applications, 47014, Meldola, Italija Advanced Accelerator Applications, 50100, Zaragoza, Španija Catalana de Dispensación SAU, 08950, Barcelona, Španija PETNET Solutions (Siemens Healthcare Limited), Nottingham, NG5 1PB, Velika Britanija PETNET Solutions (Siemens Healthcare Limited), Northwood, HA6 2RN, Velika Britanija PETNET Solutions, 91090, Lisses, Francija
If you have been given more Amyvid than you should An overdose is unlikely because you will only receive a single dose of Amyvid precisely controlled by the nuclear medicine doctor supervising the procedure.
Ker boste prejeli samo en odmerek zdravila Amyvid pod strogim nadzorom zdravnika nuklearne medicine, ki nadzira postopek, ni verjetno, da bi dobili prevelik odmerek.
MARKETING AUTHORISATION NUMBER(S) EU/1/12/805/003 (10 mL)
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/12/805/003 (10 mL)
A negative scan indicates sparse or no density of cortical β-amyloid plaques.
Negativen rezultat preiskave kaže na redke ali odsotne kortikalne βamiloidne lehe.
Total body
Maternica Celo telo
Lower large intestine wall
Stena spodnjega debelega črevesa Tanko črevo
Pharmacodynamic effects At the low chemical concentrations present in Amyvid, florbetapir (18F) does not have any detectable pharmacological activity.
Ker je florbetapir (18F) v zdravilu Amyvid prisoten v nizki kemijski koncentraciji, nima zaznavne farmakološke aktivnosti.
How Amyvid will be used
Kako uporabljati zdravilo Amyvid
Gallbladder wall
Stena žolčnika
Image interpretation errors in the estimation of brain β-amyloid neuritic plaque density, including false negatives, have been observed.
Pri ocenjevanju gostote β-amiloidnih nevritičnih leh v možganih so opazili napake pri interpretaciji slik, vključno z lažnimi negativnimi rezultati.
Nervous system disorders
Bolezni živčevja glavobol disgevzija
Close contact with infants should be restricted during the initial 24 hours following injection.
V prvih 24 urah po injiciranju je treba omejiti bližnje stike z dojenčki.
(95% CI: 51.3-84.2%)
(95-odstotni IZ: 51,3-84,2 %)
Avoid any close contact with young children and pregnant women for the 24 hours following the injection.
24 ur po injekciji se izogibajte bližnjim stikom z majhnimi otroki in nosečnicami.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V. 4.9 Preveliko odmerjanje
Red marrow
Rdeči kostni mozeg
The administration of radiopharmaceuticals creates risks for other persons (including pregnant healthcare professionals) from external radiation or contamination from spill of urine, vomiting etc.
zaradi izpostavljenosti zunanjemu sevanju ali kontaminacije zaradi razlitja urina, bruhanja, itd.
The activity per vial ranges from 800 MBq to 12000 MBq at the ToC.
Aktivnost na vialo ob ToC je v razponu med 800 MBq in 12000 MBq.
Amyvid 800 MBq/mL: One multidose vial of 10 mL capacity containing 1 to 10 mL of solution, corresponding to 800 to 8000 MBq at date and time of calibration.
Amyvid 800 MBq/ml: Ena večodmerna viala s prostornino 10 ml vsebuje 1 do 10 ml raztopine, kar ustreza 800 do 8000 MBq ob času kalibracije.
Amyvid 1900 MBq/mL: One multidose vial of 10 mL capacity containing 1 to 10 mL of solution, corresponding to 1900 to 19000 MBq at date and time of calibration.
Amyvid 1900 MBq/ml: Ena večodmerna viala s prostornino 10 ml vsebuje 1 do 10 ml raztopine, kar ustreza 1900 do 19000 MBq ob času kalibracije.
The activity per vial ranges from 1900 MBq to 28500 MBq at the ToC.
Aktivnost na vialo ob ToC je v razponu med 1900 MBq in 28500 MBq.
In vivo, correlation was assessed in end-of-life patients between florbetapir (18F) uptake in cortical grey matter and the total β-amyloid burden using 4G8 anti-amyloid antibody that stains β-amyloid found in both neuritic and diffuse plaques.
In vivo so povezavo med privzemom florbetapirja (18F) v kortikalni sivi možganovini in skupnim β-amiloidnim bremenom ocenjevali pri bolnikih ob koncu življenja z uporabo protiamiloidnega protitelesa
Amyvid contains the active substance florbetapir (18F).
Zdravilo Amyvid vsebuje učinkovino florbetapir (18F).
Close contact with infants and pregnant women should be restricted during the initial 24 hours following the injection.
V prvih 24 urah po injiciranju je treba omejiti bližnje stike z dojenčki in nosečnicami.
In the case of an amyloid positive initial visual read and negative quantitation, the physician should consider whether the positive visual interpretation might be based on tracer retention in regions outside the ROIs that contribute to the cortical average standardised uptake value ratio (SUVR).
Pozitivno zadrževanju sledilnika v regijah izven ROI, ki prispevajo k povprečnemu standardiziranemu razmerju vrednosti privzema v korteksu (SUVR - Standardised uptake value ratio).
the regions corresponding to the ROIs with elevated SUVR should be examined to determine whether there is a loss of grey/white contrast in these areas.
b. V primeru začetnega negativnega amiloidnega vizualnega odčitka in pozitivne amiloidne kvantifikacije preglejte regije, ki ustrezajo regijam zanimanja s povečanim SUVR, da boste ugotovili, ali gre za izgubo sivega/belega kontrasta na teh področjih.
Ethanol, anhydrous Sodium ascorbate Sodium chloride Water for injections
6.1 Seznam pomožnih snovi etanol, brezvodni natrijev askorbat natrijev klorid voda za injekcije
PHARMACEUTICAL FORM Solution for injection.
FARMACEVTSKA OBLIKA raztopina za injiciranje Bistra, brezbarvna raztopina.
If you get any side effects talk to your nuclear medicine doctor.
Če opazite katerega koli izmed neželenih učinkov, se posvetujte z zdravnikom nuklearne medicine.
Maximal brain uptake of florbetapir (18F) occurs within several minutes of injection, followed by rapid brain clearance during the first 30 minutes following injection.
Privzem v organe Do največjega privzema florbetapirja (18F) v možgane pride v nekaj minutah po injiciranju, nato pa se v 30
One multidose vial of 10 mL capacity contains 1 to 10 mL of solution, corresponding to 1900 to 19000 MBq at ToC.
Ena večodmerna viala s prostornino 10 ml vsebuje 1 do 10 ml raztopine, kar ustreza 1900 do 19000 MBq ob ToC.
Kidneys
Dojenje
Amyvid 1900 MBq/mL solution for injection
Amyvid 1900 MBq/ml raztopina za injiciranje
Intravenous use
intravenska uporaba večodmerno
No animal studies have been conducted to investigate the reproductive effects of florbetapir (18F) (see section 5.3).
(18F) na razmnoževanje niso izvedli (glejte poglavje 5.3).
Each mL of solution for injection contains 800 MBq of florbetapir (18F) at date and time of calibration (ToC).
En mililiter raztopine za injiciranje vsebuje 800 MBq florbetapirja (18F) ob dnevu in času kalibracije (ToC).
Amyvid 800 MBq/mL solution for injection
Amyvid 800 MBq/ml raztopina za injiciranje
One multidose vial of 15 mL capacity contains 1 to 15 mL of solution, corresponding to 800 to 12000 MBq at ToC.
Ena večodmerna viala s prostornino 15 ml vsebuje 1 do 15 ml raztopine, kar ustreza 800 do 12000 MBq ob ToC.
One multidose vial of 15 mL capacity containing 1 to 15 mL of solution, corresponding to 800 to 12000 MBq at date and time of calibration.
Ena večodmerna viala s prostornino 15 ml vsebuje 1 do 15 ml raztopine, kar ustreza 800 do 12.000 MBq ob času kalibracije.
Amyvid 800 MBq/mL solution for injection florbetapir (18F)
Amyvid 800 MBq/ml raztopina za injiciranje florbetapir (18F)
No studies have been conducted in animals to investigate the potential long term carcinogenicity, fertility, or reproductive effects of florbetapir (18F).
Pri živalih niso bile opravljene nobene študije, ki bi preiskovale morebitno dolgoročno kancerogenost,
One multidose vial of 15 mL capacity containing 1 to 15 mL of solution, corresponding to 1900 to 28.500 MBq at date and time of calibration.
Ena večodmerna viala s prostornino 15 ml vsebuje 1 do 15 ml raztopine, kar ustreza 1900 do 28.500 MBq ob času kalibracije.
(precuneus, frontal, anterior cingulate, posterior cingulate, parietal and temporal) was measured quantitatively using standardised uptake values (SUV).
Pri zaključenih kliničnih preskušanjih so privzem florbetapirja (18F) v šest vnaprej opredeljenih kortikalnih možganskih območij (precuneus, frontalna skorja, sprednja cingularna vijuga, zadnja cingularna vijuga, parietalna skorja, temporalna skorja) merili količinsko s standardiziranimi vrednostmi privzema (SUVstandardised uptake values).
Patients should be supine with the head positioned to centre the brain, including the cerebellum, in the PET scanner field of view.
Bolniki morajo ležati na hrbtu, glava pa mora biti v položaju, ki možgane, vključno z malimi možgani, postavlja v središče vidnega polja aparata za PET. Za zmanjševanje premikanja glave lahko uporabite trak ali drug fleksibilen pripomoček za omejevanje premikanja glave.
Of the patients who had been clinically diagnosed with MCI at study entry, 9 (19%) converted to clinical AD 36 months later.
Od bolnikov, ki so imeli ob vstopu v študijo klinično diagnozo zmerne kognitivne okvare, jih je 36
Amyvid 800 MBq/mL: 1 mL of solution for injection contains 800 MBq of florbetapir (18F) at the date and time of calibration.
Amyvid 800 MBq/ml raztopina za injiciranje En mililiter raztopine za injiciranje vsebuje 800 MBq florbetapirja (18F) ob času kalibracije (ToC- time of calibration).
One multidose vial of 15 mL capacity contains 1 to 15 mL of solution, corresponding to 1900 to 28500 MBq at ToC.
Ena večodmerna viala s prostornino 15 ml vsebuje 1 do 15 ml raztopine, kar ustreza 1900 do 28500 MBq ob ToC.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI Neuporabljen material zavrzite v skladu z lokalnimi predpisi.
One multidose vial of 10 mL capacity contains 1 to 10 mL of solution, corresponding to 800 to 8000 MBq at ToC.
Ena večodmerna viala s prostornino 10 ml vsebuje 1 do 10 ml raztopine, kar ustreza 800 do 8000 MBq ob
BATCH NUMBER Lot
Lot Št. viale
No animal toxicology and safety pharmacology studies have been performed with florbetapir (18F).
S florbetapirjem (18F) niso izvedli toksikoloških študij na živalih ali študij farmakološke varnosti.
Multidose
Odmerjanje
Amyvid 1900 MBq/mL solution for injection Amyvid 800 MBq/mL solution for injection florbetapir (18F)
Navodilo za uporabo Amyvid 1900 MBq/ml raztopina za injiciranje Amyvid 800 MBq/ml raztopina za injiciranje florbetapir (18F)
Please refer to the SmPC {SmPC should be included in the box}.
Glejte Povzetek glavnih značilnosti zdravila {Povzetek glavnih značilnosti zdravila mora biti priložen v škatli}.
Contact your nuclear medicine doctor if you have any questions.
Če imate kakršno koli vprašanje, se posvetujte z zdravnikom nuklearne medicine.
A recent co-registered computed tomography (CT) scan or magnetic resonance (MR) imaging of the patient to get a fused PET-CT or PET-MR image is recommended in cases of uncertainty about the location of grey matter and of the grey/white matter border in the PET scan (see section 4.4.
V primeru dvomov o lokaciji sive možganovine in meje med sivo in belo možganovino na PET-posnetku se v kratkem časovnem razmaku priporoča tudi sočasno slikanje z računalniško tomografijo (CT) ali magnetno resonanco (MR), da se pridobi združeno sliko PET-CT
How Amyvid is stored
Shranjevanje zdravila Amyvid
Each mL of solution for injection contains 800 MBq of florbetapir (18F) at the date and time of calibration (ToC).
En mililiter raztopine za injiciranje vsebuje 1900 MBq florbetapirja (18F) ob dnevu in času kalibracije (ToC).
NAME OF THE MEDICINAL PRODUCT Amyvid 800 MBq/mL solution for injection Amyvid 1900 MBq/mL solution for injection
Amyvid 800 MBq/ml raztopina za injiciranje Amyvid 1900 MBq/ml raztopina za injiciranje
Ovaries
Jajčniki
Dose
- dojite
Urinary bladder wall
Ščitnica Stena sečnega mehurja
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Amyvid 800 MBq/mL solution for injection florbetapir (18F)
IME ZDRAVILA IN POT(I) UPORABE Amyvid 800 MBq/ml raztopina za injiciranje florbetapir (18F) intravenska uporaba
If you are pregnant
Če dojite
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Amyvid 1900 MBq/mL solution for injection florbetapir (18F)
IME ZDRAVILA IN POT(I) UPORABE Amyvid 1900 MBq/ml raztopina za injiciranje florbetapir (18F) intravenska uporaba
Healthy controls show relatively low levels of florbetapir (18F) retention in cortex and cerebellum.
Zadrževanje florbetapirja (18F) v skorji in malih možganih pri zdravih kontrolah je razmeroma majhno.
Renal impairment and hepatic impairment
Žilne bolezni vročinski oblivi
Pancreas
Vranica
Pack size
Velikosti pakiranja
NAME OF THE MEDICINAL PRODUCT Amyvid 1900 MBq/mL solution for injection florbetapir (18F)
Amyvid 1900 MBq/ml raztopina za injiciranje florbetapir (18F)
Amyvid 1900 MBq/mL: 1 mL of solution for injection contains 1900 MBq of florbetapir (18F) at the date and time of calibration.
Amyvid 1900 MBq/ml raztopina za injiciranje En mililiter raztopine za injiciranje vsebuje 1900 MBq florbetapirja (18F) ob ToC.
Upper large intestine wall
Stena srca Ledvice Jetra
Amyvid images should only be interpreted by readers trained in the interpretation of PET images with florbetapir (18F).
Slike z zdravilom Amyvid lahko interpretirajo le odčitovalci, usposobljeni za interpretacijo PET
Highest quality standards
Najvišji standardi kakovosti
The work programme of the European Medicines Agency for 2012 is influenced by a number of factors, among which are:
Na delovni program Evropske agencije za zdravila za leto 2012 vplivajo številni dejavniki, kot so:
Access to documents will remain an area that consumes significant resources.
Dostop do dokumentov bo ostalo področje, ki porabi precej sredstev.
The Agency's website will be adapted to include a single point of entry for all requests for documents or information.
Spletna stran agencije bo prilagojena, da bo vključevala enotno vstopno točko za vse zahtevke za dokumente ali informacije.
The Agency will reinforce its contribution to the treatment of elderly patients and pregnant women.
Agencija bo okrepila svoj prispevek k zdravljenju starejših bolnikov in nosečnic.
Communication and engagement with stakeholders
Komunikacija in sodelovanje z zainteresiranimi stranmi
Agreement on these issues will pave the way for further measures that will allow the Agency to move from reactive to proactive publication of various documents.
Dogovor o teh vprašanjih bo utrl pot nadaljnjim ukrepom, kar bo agenciji omogočilo prehod z reaktivnega na proaktivno objavljanje različnih dokumentov.
Main committee meetings during the critical July 2012 period will be hosted by national competent authorities and the European Commission.
Glavne sestanke odborov v tem zahtevnem obdobju, tj. juliju 2012, bodo gostili pristojni nacionalni organi in Evropska komisija.
The majority of requirements of the new legislation that will help to prevent entry into the legal supply chain of falsified medicinal products will come into force in January 2013, but preparatory work has to be undertaken in 2012.
Večina zahtev iz nove zakonodaje, ki bodo pomagale preprečevati vstop ponarejenih zdravil v zakonito dobavno verigo, bo začela veljati januarja 2013, vendar bodo priprave na to izvedene že v letu 2012.
Activities contributing to public health are given the highest priority, followed by those that will increase transparency and improve communication, then by simplification measures.
Dejavnosti, ki prispevajo k javnemu zdravju, imajo največjo prednost, sledijo dejavnosti, ki bodo povečale preglednost in izboljšale komunikacijo, in nato ukrepi za poenostavitev.
The Agency and its network partners believe that the latter would save resources in the long term.
Agencija in njeni partnerji v mreži so prepričani, da bi z zadnjenavedenim dolgoročno prihranili sredstva.
The Agency and its partners have set priorities for the stepwise implementation of the legislation in line with available resources.
Agencija in njeni partnerji so določili prednostne naloge za postopno izvajanje zakonodaje v skladu z razpoložljivimi sredstvi.
The volume of core activities will remain at a similar level to last year, with a marginal increase in certain areas.
Obseg ključnih dejavnosti ostaja na podobni ravni kot prejšnje leto, omejeno povečanje pa je zaznati le na nekaterih področjih.
The work programme takes into account the above factors, the broader context of the Agency's legislative, economic, social and technological environment, and relevant measures outlined in the implementation plan for the Agency's 'Road map to 2015'.
V delovnem programu so upoštevani zgoraj navedeni dejavniki, širši okvir zakonodajnega, gospodarskega, socialnega in tehnološkega okolja agencije ter ustrezni ukrepi, ki so opisani v izvedbenem načrtu za „časovni načrt agencije do leta 2015“.
This will create an opportunity to test arrangements in case of logistical disruptions and to increase the use of virtual meetings for core activities.
To bo priložnost za preskus ureditev, ki veljajo v primeru logističnih težav, in pogostejšo uporabo virtualnih sestankov za glavne dejavnosti.
Public-health needs and availability of medicines
Potrebe javnega zdravstva in razpoložljivost zdravil
Work is ongoing within the network to define what information is considered commercially confidential and how to best comply with protection of personal data.
V okviru mreže poteka delo za določitev, katere informacije se štejejo za poslovno skrivnost in kako najbolje izpolnjevati zahteve glede varstva osebnih podatkov.
One of the pillars of the implementation will be the strengthening of the Agency's collaboration with the national competent authorities in the area of communication and provision of information.
Eden od stebrov izvajanja bo izboljšanje sodelovanja agencije z nacionalnimi pristojnimi organi pri komunikaciji in zagotavljanju informacij.
Following the implementation of the revised policies on handling of conflicts of interests in 2011, the Agency will focus on ensuring the full implementation and effective functioning of its updated policies on managing potential conflicts of interests with respect to the Management Board, experts and staff.
Agencija se bo po uvedbi revidirane politike o upravljanju navzkrižij interesov v letu 2011 osredotočila na zagotavljanje popolnega izvajanja in učinkovitega delovanja svojih posodobljenih politik o obvladovanju možnih navzkrižij interesov v zvezi z upravnim odborom, strokovnjaki in osebjem.
The Agency will also finalise its transparency policy, following the outcome of the public consultation.
Poleg tega bo agencija v skladu z rezultati javnega posvetovanja dokončala tudi politiko preglednosti.
Conducting ongoing scientific responsibilities to the highest quality standards remains the Agency's main priority.
Izpolnjevanje tekočih obveznosti na področju znanosti v skladu z najvišjimi standardi kakovosti ostaja glavna prednostna naloga agencije.
The extent and timetable for the contribution from the veterinary sector will be determined by the resources available, bearing in mind the priority that must be placed on maintaining core scientific responsibilities.
Na obseg in časovni razpored prispevkov veterinarskega sektorja bodo vplivala razpoložljiva sredstva, ob upoštevanju, da je treba dati prednost ohranjanju glavnih odgovornosti na področju znanosti.